106 related articles for article (PubMed ID: 26704964)
1. Economic Benefit-Cost Analysis of Select Secondary Prevention Interventions in LMIC.
Nugent R; Brouwer E
Glob Heart; 2015 Dec; 10(4):319-21. PubMed ID: 26704964
[TBL] [Abstract][Full Text] [Related]
2. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs.
Lim SS; Gaziano TA; Gakidou E; Reddy KS; Farzadfar F; Lozano R; Rodgers A
Lancet; 2007 Dec; 370(9604):2054-62. PubMed ID: 18063025
[TBL] [Abstract][Full Text] [Related]
3. The global impact of noncommunicable diseases: estimates and projections.
Manton KG
World Health Stat Q; 1988; 41(3-4):255-66. PubMed ID: 3232413
[TBL] [Abstract][Full Text] [Related]
4. Can China achieve a one-third reduction in premature mortality from non-communicable diseases by 2030?
Li Y; Zeng X; Liu J; Liu Y; Liu S; Yin P; Qi J; Zhao Z; Yu S; Hu Y; He G; Lopez AD; Gao GF; Wang L; Zhou M
BMC Med; 2017 Jul; 15(1):132. PubMed ID: 28693510
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America.
Pichon-Riviere A; Augustovski F; Bardach A; Colantonio L;
Value Health; 2011; 14(5 Suppl 1):S51-9. PubMed ID: 21839900
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk.
Murray CJ; Lauer JA; Hutubessy RC; Niessen L; Tomijima N; Rodgers A; Lawes CM; Evans DB
Lancet; 2003 Mar; 361(9359):717-25. PubMed ID: 12620735
[TBL] [Abstract][Full Text] [Related]
8. Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.
Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
Cardiovasc Ther; 2013 Feb; 31(1):45-52. PubMed ID: 21884025
[TBL] [Abstract][Full Text] [Related]
9. Understanding The Relationships Between Noncommunicable Diseases, Unhealthy Lifestyles, And Country Wealth.
Bollyky TJ; Templin T; Andridge C; Dieleman JL
Health Aff (Millwood); 2015 Sep; 34(9):1464-71. PubMed ID: 26355047
[TBL] [Abstract][Full Text] [Related]
10. The consequences of tobacco tax on household health and finances in rich and poor smokers in China: an extended cost-effectiveness analysis.
Verguet S; Gauvreau CL; Mishra S; MacLennan M; Murphy SM; Brouwer ED; Nugent RA; Zhao K; Jha P; Jamison DT
Lancet Glob Health; 2015 Apr; 3(4):e206-16. PubMed ID: 25772692
[TBL] [Abstract][Full Text] [Related]
11. Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services.
Bertram MY; Sweeny K; Lauer JA; Chisholm D; Sheehan P; Rasmussen B; Upreti SR; Dixit LP; George K; Deane S
Lancet; 2018 May; 391(10134):2071-2078. PubMed ID: 29627159
[TBL] [Abstract][Full Text] [Related]
12. Health and economic implications of a tobacco-free society.
Warner KE
JAMA; 1987 Oct; 258(15):2080-6. PubMed ID: 3656624
[TBL] [Abstract][Full Text] [Related]
13. Estimates of global and regional premature cardiovascular mortality in 2025.
Roth GA; Nguyen G; Forouzanfar MH; Mokdad AH; Naghavi M; Murray CJ
Circulation; 2015 Sep; 132(13):1270-82. PubMed ID: 26408271
[TBL] [Abstract][Full Text] [Related]
14. The burden of smoking-related diseases in Brazil: mortality, morbidity and costs.
Pinto MT; Pichon-Riviere A; Bardach A
Cad Saude Publica; 2015 Jun; 31(6):1283-97. PubMed ID: 26200375
[TBL] [Abstract][Full Text] [Related]
15. Costs, benefits, and effectiveness of interventions for the prevention, treatment, and control of cardiovascular diseases and diabetes in Africa.
Mendis S; Chestnov O
Prog Cardiovasc Dis; 2013; 56(3):314-21. PubMed ID: 24267438
[TBL] [Abstract][Full Text] [Related]
16. Estimates of global mortality attributable to smoking in 2000.
Ezzati M; Lopez AD
Lancet; 2003 Sep; 362(9387):847-52. PubMed ID: 13678970
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of full coverage of the medical management of smoking cessation in France.
Chevreul K; Cadier B; Durand-Zaleski I; Chan E; Thomas D
Tob Control; 2014 May; 23(3):223-30. PubMed ID: 23197369
[TBL] [Abstract][Full Text] [Related]
18. Disease and demography: a systems-dynamic cohort-component population model to assess the implications of disease-specific mortality targets.
Husain MJ; Datta BK; Kostova D
BMJ Open; 2021 May; 11(5):e043313. PubMed ID: 33986047
[TBL] [Abstract][Full Text] [Related]
19. Reducing the burden of smoking world-wide: effectiveness of interventions and their coverage.
Jha P; Chaloupka FJ; Corrao M; Jacob B
Drug Alcohol Rev; 2006 Nov; 25(6):597-609. PubMed ID: 17132576
[TBL] [Abstract][Full Text] [Related]
20. Chronic non-communicable diseases.
Unwin N; Alberti KG
Ann Trop Med Parasitol; 2006; 100(5-6):455-64. PubMed ID: 16899148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
